Organogenesis Holdings Inc. (ORGO)
ORGO Stock Price Chart
Explore Organogenesis Holdings Inc. interactive price chart. Choose custom timeframes to analyze ORGO price movements and trends.
ORGO Company Profile
Discover essential business fundamentals and corporate details for Organogenesis Holdings Inc. (ORGO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
5 Jan 2017
Employees
869.00
Website
https://organogenesis.comCEO
Gary S. Gillheeney
Description
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Financial Timeline
Browse a chronological timeline of Organogenesis Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.35, while revenue estimate is $54.27m.
Earnings released on 7 May 2026
EPS came in at -$0.37 falling short of the estimated -$0.29 by -27.59%, while revenue for the quarter reached $36.25m , missing expectations by -16.21%.
Earnings released on 26 Feb 2026
EPS came in at $0.31 surpassing the estimated $0.22 by +44.19%, while revenue for the quarter reached $225.07m , beating expectations by +30.36%.
Earnings released on 6 Nov 2025
EPS came in at $0.18 falling short of the estimated $0.21 by -14.29%, while revenue for the quarter reached $150.86m , missing expectations by -12.63%.
Earnings released on 7 Aug 2025
EPS came in at -$0.09 falling short of the estimated $0.07 by -228.57%, while revenue for the quarter reached $101.01m , missing expectations by -24.68%.
Earnings released on 8 May 2025
EPS came in at -$0.13 falling short of the estimated $0.04 by -425.00%, while revenue for the quarter reached $86.69m , missing expectations by -4.49%.
Earnings released on 27 Feb 2025
EPS came in at $0.04 surpassing the estimated -$0.03 by +233.33%, while revenue for the quarter reached $126.66m , beating expectations by +15.56%.
Earnings released on 12 Nov 2024
EPS came in at $0.09 surpassing the estimated $0.01 by +700.00%, while revenue for the quarter reached $115.18m , beating expectations by +7.71%.
Earnings released on 8 Aug 2024
EPS came in at -$0.13 falling short of the estimated -$0.02 by -550.00%, while revenue for the quarter reached $130.23m , beating expectations by +6.88%.
Earnings released on 9 May 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -25.00%, while revenue for the quarter reached $109.98m , beating expectations by +8.83%.
Earnings released on 29 Feb 2024
EPS came in at -$0.00 falling short of the estimated -$0.00 by -100.47%, while revenue for the quarter reached $99.65m , missing expectations by -8.62%.
Earnings released on 9 Nov 2023
EPS came in at $0.02 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $108.53m , beating expectations by +1.24%.
Earnings released on 9 Aug 2023
EPS came in at $0.04 surpassing the estimated $0.03 by +60.00%, while revenue for the quarter reached $117.32m , beating expectations by +1.93%.
Earnings released on 10 May 2023
EPS came in at -$0.02 matching the estimated -$0.02, while revenue for the quarter reached $107.64m , beating expectations by +12.71%.
Earnings released on 1 Mar 2023
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $115.52m , missing expectations by -5.62%.
Earnings released on 9 Nov 2022
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $116.86m , missing expectations by -3.30%.
Earnings released on 9 Aug 2022
EPS came in at $0.07 falling short of the estimated $0.08 by -12.50%, while revenue for the quarter reached $121.40m , beating expectations by +0.41%.
Earnings released on 10 May 2022
EPS came in at $0.01 falling short of the estimated $0.05 by -80.00%, while revenue for the quarter reached $98.12m , beating expectations by +2.26%.
Earnings released on 1 Mar 2022
EPS came in at $0.39 surpassing the estimated $0.08 by +387.50%, while revenue for the quarter reached $128.56m , beating expectations by +3.08%.
Earnings released on 9 Nov 2021
EPS came in at $0.10 surpassing the estimated $0.06 by +66.67%, while revenue for the quarter reached $113.75m , beating expectations by +0.96%.
Earnings released on 9 Aug 2021
EPS came in at $0.15 surpassing the estimated $0.07 by +114.29%, while revenue for the quarter reached $123.20m , beating expectations by +25.70%.
ORGO Stock Performance
Access detailed ORGO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
